Coeptis Therapeutics — Bull Horn Holdings — SPAC Merger (July 2022)
31 slides from Coeptis Therapeutics's SPAC merger presentation, Jul 6, 2022

Slide 1: Coeptis Therapeutics, Inc. Corporate Overview
1 © 2022 Coeptis Therapeutics, Inc. All rights reserved Coeptis Therapeutics, Inc. Corporate Overview

Slide 2: Important Legal Disclaimers
2 © 2022 Coeptis Therapeutics, Inc. All rights reserved Important Legal Disclaimers This presentation (the “Presentation”) has been prepared for informational purposes only to assist interested parties in eval uat ing an investment in connection with a proposed business combination (the “Business Co

Slide 3: Important Legal Disclaimers cont'd.
3 © 2022 Coeptis Therapeutics, Inc. All rights reserved Important Legal Disclaimers cont’d. Participants in Solicitation: Bull Horn and Coeptis and their respective directors and executive officers may, under SEC rules, be deemed to be participants in the solicitation of proxies or consents of Bull

Slide 4: Important Legal Disclaimers cont'd.
4 © 2022 Coeptis Therapeutics, Inc. All rights reserved Important Legal Disclaimers cont’d. This Presentation does not contain any information that should be considered by Bull Horn’s or Coeptis’ respective shareholde rs concerning the proposed Business Combination and is not intended to constitute

Slide 5: Important Legal Disclaimers cont'd.
5 © 2022 Coeptis Therapeutics, Inc. All rights reserved Important Legal Disclaimers cont’d. No Representation: Neither Bull Horn nor Coeptis, nor any of their respective subsidiaries, shareholders, affiliates, representatives, control persons, partners, members, managers, directors, officers, employ

Slide 6: Important Legal Disclaimers cont'd.
6 © 2022 Coeptis Therapeutics, Inc. All rights reserved Important Legal Disclaimers cont’d. The below list of risk factors has been prepared as part of the Business Combination. The risks presented below are a subset of the general risks related to the business of Coeptis and the proposed Business C

Slide 7: Important Legal Disclaimers cont'd.
7 © 2022 Coeptis Therapeutics, Inc. All rights reserved Important Legal Disclaimers cont’d. - If the Business Combination is consummated, there is no assurance that we will achieve the intended benefits of the Business Combination; - Adverse impacts from the pandemic involving the novel coronavirus

Slide 8: Important Legal Disclaimers cont'd.
8 © 2022 Coeptis Therapeutics, Inc. All rights reserved Important Legal Disclaimers cont’d. - The drug development and approval process is uncertain, time - consuming and expensive; - Competition in the biotechnology and pharmaceutical industries may result in competing products, superior marketing

Slide 9: Cautionary Note Regarding Forward-Looking Statements
9 © 2022 Coeptis Therapeutics, Inc. All rights reserved Cautionary Note Regarding Forward - Looking Statements Certain statements in this Presentation, and statements by management or other persons acting by or on behalf of Bull Horn or Co eptis made in connection with this Presentation, constitute

Slide 10: Coeptis Therapeutics
10 © 2022 Coeptis Therapeutics, Inc. All rights reserved COEPTIS THERAPEUTICS We are a Pittsburgh, PA based pharmaceutical company founded by an experienced team developing innovative cell therapy platforms in oncology .

Slide 11: Merger Agreement with Bull Horn Holdings
11 © 2022 Coeptis Therapeutics, Inc. All rights reserved MERGER AGREEMENT WITH BULL HORN HOLDINGS CD38+ CANCERS – INITIAL GEAR - NK TARGET OPTION FOR CAR - T PLATFORM WITH MULTIPLE APPLICATIONS OPTION FOR ENTOLIMOD – CLINICAL STAGE, TLR5 AGONIST Announced entry into definitive merger agreement with

Slide 12: Definitive merger agreement and key transaction terms
12 © 2022 Coeptis Therapeutics, Inc. All rights reserved Coeptis entered into definitive merger agreement for a business combination that will result in Coeptis becoming a wholly - owned subsidiary of Bull Horn Holdings Corp. (Nasdaq: BHSE), a special purpose acquisition company (SPAC). Under the te

Slide 13: Multiple Growth Drivers – Pre/Post Merger
13 © 2022 Coeptis Therapeutics, Inc. All rights reserved Multiple Growth Drivers – Pre/Post Merger Business Combination values Coeptis at $175 million (subject to adjustments) . Business Combination value agreed to prior to TRL5 agonist and Pitt agreements, suggesting near - term and longer - range

Slide 14: VyGen-Bio option agreements
14 © 2022 Coeptis Therapeutics, Inc. All rights reserved Coeptis entered into two exclusive option agreements with VyGen - Bio, Inc., a majority - owned subsidiary of Vycellix, Inc., involving technologies designed to improve the treatment of CD38 - related cancers. Coeptis will assist VyGen - Bio i

Slide 15: GEAR-NK (CD38) Strategy
15 © 2022 Coeptis Therapeutics, Inc. All rights reserved IMMUNOTHERAPY CHALLENGES Various immunotherapies for CD38+ tumors are designed to find and kill cells that express the CD38 antigen; therefore, CD38+ NK cells are likely to become collateral damage and with their eradication, the overall anti

Slide 16: Current anti-CD38 pathway vs pathway with GEAR-NK
16 © 2022 Coeptis Therapeutics, Inc. All rights reserved Animations herein are provided as visual aids to help articulate hypothesized proof - of - concept in a general manner and do not de pict precise scientific mechanisms - of - action. Anti - CD38 mAbs (Infused antibodies from current cancer tre

Slide 17: CD38-GEAR-NK – Market Opportunity
17 © 2022 Coeptis Therapeutics, Inc. All rights reserved CD38 - GEAR - NK – Market Opportunity CD38 - GEAR - NK could change how CD38 - related cancers are treated by protecting CD38+ NK cells from destruction by anti - CD38 mAbs. Opportunity to improve the treatment of CD38 - related cancers, inclu

Slide 18: CD38-Diagnostic – Product Overview
18 © 2022 Coeptis Therapeutics, Inc. All rights reserved CD38 - Diagnostic is an in vitro screening tool to be used prior to initiation of mAb therapy. Being developed to pre - determine which cancer patients are most likely to benefit from targeted anti - CD38 mAb therapies , either as monotherapy

Slide 19: CD38-Diagnostic – Market Opportunity
19 © 2022 Coeptis Therapeutics, Inc. All rights reserved CD38 - Diagnostic – Market Opportunity Could prevent patients from being subjected to ineffective therapy and enable significant savings to healthcare systems CD38 - Diagnostic provides opportunity to make more cost - effective medical decisio

Slide 20: CD38-Diagnostic – Value Proposition
20 © 2022 Coeptis Therapeutics, Inc. All rights reserved FLEXIBILITY SPEED TO MARKET RETURN ON INVESTMENT Designed to be used as a companion with CD38 GEAR - NK or as a standalone diagnostic screening test to determine which immunotherapies may be responsive to CD38+ tumors Opportunity to expand the

Slide 21: GEAR Platform Advantages
21 © 2022 Coeptis Therapeutics, Inc. All rights reserved Each GEAR platform being designed to be deployed independently or collectively to further bolster the likelihood of a durable therapeutic response . GEAR Diagnostic being designed to determine the most appropriate anti - CD38 mAb . GEAR NK bei

Slide 22: Coeptis Option – University of Pittsburgh
22 © 2022 Coeptis Therapeutics, Inc. All rights reserved Coeptis entered into an exclusive option agreement with the University of Pittsburgh for the rights to negotiate licenses to three CAR - T technologies that offer the potential to address a range of hematologic and solid tumors. Exclusive opti

Slide 23: CAR-T Platform – Market Opportunities
23 © 2022 Coeptis Therapeutics, Inc. All rights reserved CAR - T Platform – Market Opportunities CAR - T offers the potential to revolutionize cancer treatment; however, there remain shortcomings with current CAR - T therapies that could enable the technology to be utilized with additional types of

Slide 24: CAR-T Platform – Core Opportunities
24 © 2022 Coeptis Therapeutics, Inc. All rights reserved Creating a universal CAR - T system that maintains a high - binding affinity , while also offering greater control over toxicity . Developing a technology that can target multiple antigens simultaneously . CAR - T Platform – Core Opportunities

Slide 25: Coeptis Strategic Agreement – TLR5 Agonist Platform
25 © 2022 Coeptis Therapeutics, Inc. All rights reserved Coeptis entered into a strategic agreement giving it the right to acquire toll - like receptor 5 (TLR5) agonist platform, including entolimod, a clinical - stage product currently being developed as a treatment for acute radiation syndrome. Co

Slide 26: TLR5 Agonist – Treatment Opportunities
26 © 2022 Coeptis Therapeutics, Inc. All rights reserved TLR5 Agonist – Treatment Opportunities TLR5 is an innate immunity receptor, which when activated, triggers nuclear factor kappa B (NF - kB) signaling, mobilizing an innate immune response that drives expression of numerous genes . Entolimod is

Slide 27: Coeptis Scientific Advisory Board
27 © 2022 Coeptis Therapeutics, Inc. All rights reserved Coeptis Scientific Advisory Board Head of the Gene and Cell Therapy Group, Division of Hematology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm Evren Alici M.D., Ph.D. Arnika K. Wagner, Ph.D. Assista

Slide 28: Coeptis Management Team
28 © 2022 Coeptis Therapeutics, Inc. All rights reserved COEPTIS MANAGEMENT TEAM Dave Mehalick Co - Founder, President & CEO 30 years of diverse business experience in healthcare, information technology and finance including consulting, capital markets, private equity, and investments Christine Shee

Slide 29: Anticipated Milestones
29 © 2022 Coeptis Therapeutics, Inc. All rights reserved Anticipated Milestones Expand IP portfolio around GEAR - NK and GEAR Diagnostic Expand ownership of VyGen - Bio and entire GEAR Platform Complete merger agreement with Bull Horn Holdings COEP stock to begin trading on Nasdaq following Bull Hor

Slide 30: Coeptis Value Proposition
30 © 2022 Coeptis Therapeutics, Inc. All rights reserved Coeptis Value Proposition Cell and gene therapies have the potential to “disrupt” current treatment paradigms. Early - stage development assets in this space are being routinely acquired by larger Pharma companies. Entolimod, if acquired, woul

Slide 31: Coeptis Investor Relations Contact
31 © 2022 Coeptis Therapeutics, Inc. All rights reserved Coeptis Investor Relations Contact: Bill Borden Senior Vice President Tiberend Strategic Advisors Mobile: 732 - 910 - 1620 [email protected] coeptistx.com
Source: SEC EDGAR · 425 filed Jul 6, 2022
More decks from Coeptis Therapeutics Inc
Investor Presentation (December 2023)20 slides · Dec 5, 2023
Investor Presentation (June 2023)29 slides · Jun 6, 2023
Investor Presentation (November 2022)27 slides · Nov 3, 2022
SPAC Merger (September 2022)30 slides · Sep 21, 2022
SPAC Merger (September 2022)29 slides · Sep 7, 2022
SPAC Merger (July 2022)31 slides · Jul 6, 2022